Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma 2Spinal Cord Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrent Squamous Cell Lung Carcinoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoid Interstitial Pneumonia 1Fallopian Tube Neoplasms 1Astrocytoma 1

Interventions

atezolizumab 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Docetaxel 1Disulfides 1Cisplatin 1Cetuximab 1Carboplatin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoid Interstitial Pneumonia × Disulfides × Clear all
NCT05063552 2026-05-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡